CA2028746C - Pharmaceutical compositions and methods for treating the symptoms of overindulgence - Google Patents
Pharmaceutical compositions and methods for treating the symptoms of overindulgenceInfo
- Publication number
- CA2028746C CA2028746C CA002028746A CA2028746A CA2028746C CA 2028746 C CA2028746 C CA 2028746C CA 002028746 A CA002028746 A CA 002028746A CA 2028746 A CA2028746 A CA 2028746A CA 2028746 C CA2028746 C CA 2028746C
- Authority
- CA
- Canada
- Prior art keywords
- per dose
- pharmaceutical composition
- accordance
- acetaminophen
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 28
- 208000024891 symptom Diseases 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 title abstract description 12
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims abstract description 39
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims abstract description 18
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims abstract description 18
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 claims abstract description 17
- 239000003485 histamine H2 receptor antagonist Substances 0.000 claims abstract description 15
- 230000000202 analgesic effect Effects 0.000 claims abstract description 6
- 229960005489 paracetamol Drugs 0.000 claims abstract 13
- 239000000938 histamine H1 antagonist Substances 0.000 claims abstract 9
- 229940126409 proton pump inhibitor Drugs 0.000 claims abstract 5
- 239000000612 proton pump inhibitor Substances 0.000 claims abstract 5
- 210000004211 gastric acid Anatomy 0.000 claims abstract 3
- 230000002401 inhibitory effect Effects 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 14
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 12
- 229960000381 omeprazole Drugs 0.000 claims description 12
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 10
- 229960002009 naproxen Drugs 0.000 claims description 10
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 10
- 101150056637 Hrh2 gene Proteins 0.000 claims description 7
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 claims description 6
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 claims description 6
- 229960001419 fenoprofen Drugs 0.000 claims description 6
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 6
- 229960000991 ketoprofen Drugs 0.000 claims description 6
- 229940013798 meclofenamate Drugs 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000007894 caplet Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- -1 oxicams Chemical class 0.000 claims 10
- 229960001380 cimetidine Drugs 0.000 claims 8
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims 8
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 7
- 229960000520 diphenhydramine Drugs 0.000 claims 7
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 7
- 229960001680 ibuprofen Drugs 0.000 claims 7
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 claims 6
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 claims 6
- 229960000428 carbinoxamine Drugs 0.000 claims 6
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 claims 6
- 229960003564 cyclizine Drugs 0.000 claims 6
- UVKZSORBKUEBAZ-UHFFFAOYSA-N cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 claims 6
- 229960000930 hydroxyzine Drugs 0.000 claims 6
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 claims 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 6
- 229960001474 meclozine Drugs 0.000 claims 6
- 229960000582 mepyramine Drugs 0.000 claims 6
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 claims 6
- 229960003910 promethazine Drugs 0.000 claims 6
- 229960000620 ranitidine Drugs 0.000 claims 6
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims 6
- 229960003223 tripelennamine Drugs 0.000 claims 6
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 claims 5
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims 5
- 229960001596 famotidine Drugs 0.000 claims 5
- 229960003464 mefenamic acid Drugs 0.000 claims 4
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims 4
- 229960002702 piroxicam Drugs 0.000 claims 4
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 4
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims 4
- 229960000894 sulindac Drugs 0.000 claims 4
- 229960001017 tolmetin Drugs 0.000 claims 4
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 claims 4
- 230000000903 blocking effect Effects 0.000 claims 3
- 229960000905 indomethacin Drugs 0.000 claims 3
- 102000003834 Histamine H1 Receptors Human genes 0.000 claims 2
- 108090000110 Histamine H1 Receptors Proteins 0.000 claims 2
- HEFNNWSXXWATRW-JTQLQIEISA-N dexibuprofen Chemical compound CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-JTQLQIEISA-N 0.000 claims 2
- BOIZHGCLUSQNLD-UHFFFAOYSA-N acetic acid;1h-indole Chemical class CC(O)=O.C1=CC=C2NC=CC2=C1 BOIZHGCLUSQNLD-UHFFFAOYSA-N 0.000 claims 1
- 229940111133 antiinflammatory and antirheumatic drug oxicams Drugs 0.000 claims 1
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 claims 1
- ZWJINEZUASEZBH-UHFFFAOYSA-N fenamic acid Chemical class OC(=O)C1=CC=CC=C1NC1=CC=CC=C1 ZWJINEZUASEZBH-UHFFFAOYSA-N 0.000 claims 1
- 239000008297 liquid dosage form Substances 0.000 claims 1
- 239000007935 oral tablet Substances 0.000 claims 1
- 229940096978 oral tablet Drugs 0.000 claims 1
- 150000005599 propionic acid derivatives Chemical class 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 235000019441 ethanol Nutrition 0.000 description 19
- 239000003826 tablet Substances 0.000 description 17
- 208000029618 autoimmune pulmonary alveolar proteinosis Diseases 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 12
- 206010019233 Headaches Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 231100000869 headache Toxicity 0.000 description 11
- 238000011282 treatment Methods 0.000 description 10
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 9
- 108010083204 Proton Pumps Proteins 0.000 description 9
- 201000006549 dyspepsia Diseases 0.000 description 8
- 208000024798 heartburn Diseases 0.000 description 8
- 210000004877 mucosa Anatomy 0.000 description 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 5
- 229960001138 acetylsalicylic acid Drugs 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 241001106067 Atropa Species 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US430,837 | 1982-09-30 | ||
| US43083789A | 1989-11-02 | 1989-11-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2028746A1 CA2028746A1 (en) | 1991-05-03 |
| CA2028746C true CA2028746C (en) | 1995-12-26 |
Family
ID=23709269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002028746A Expired - Lifetime CA2028746C (en) | 1989-11-02 | 1990-10-31 | Pharmaceutical compositions and methods for treating the symptoms of overindulgence |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0426479B1 (enExample) |
| JP (1) | JPH03206052A (enExample) |
| KR (1) | KR910009254A (enExample) |
| AT (1) | ATE101515T1 (enExample) |
| AU (1) | AU646230B2 (enExample) |
| CA (1) | CA2028746C (enExample) |
| DE (1) | DE69006684T2 (enExample) |
| ES (1) | ES2057439T3 (enExample) |
| GR (1) | GR1002097B (enExample) |
| IE (1) | IE64953B1 (enExample) |
| IN (1) | IN171746B (enExample) |
| NZ (1) | NZ235877A (enExample) |
| PT (1) | PT95753A (enExample) |
| ZA (1) | ZA908775B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69228738D1 (de) * | 1991-12-06 | 1999-04-29 | Glaxo Group Ltd | Zusammensetzungen zur Behandlung von entzündlichen Zuständen oder Analgesie, die Ranitidin Wismuth Citrat und einen NSAID enthalten |
| AU4931693A (en) * | 1992-09-29 | 1994-04-26 | Mcneil-Ppc, Inc. | Ibuprofen-h2 antagonist combinations |
| GB9221414D0 (en) * | 1992-10-13 | 1992-11-25 | Glaxo Group Ltd | Pharmaceutical compositions |
| US5648355A (en) * | 1994-02-09 | 1997-07-15 | Kos Pharmaceutical, Inc. | Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin |
| SE9600072D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients II |
| SE9600070D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
| WO1998058637A1 (en) * | 1996-06-20 | 1998-12-30 | Mcneil-Ppc | Acetaminophen and diphenhydramine analgesics |
| ZA975444B (en) * | 1996-06-20 | 1998-12-21 | Mcneil Ppc Inc | Acetaminophen and meclizine hydrochloride analgesics |
| DE19801811B4 (de) * | 1998-01-19 | 2004-12-23 | Stada Arzneimittel Ag | Pharmazeutische Zubereitung zur oralen Verabreichung |
| US7906153B2 (en) | 1998-04-08 | 2011-03-15 | Theta Biomedical Consulting & Development Co., Inc. | Anti-inflammatory compositions for treating multiple sclerosis |
| US20050220909A1 (en) | 2004-03-30 | 2005-10-06 | Theoharides Theoharis C | Composition for protection against superficial vasodilator flush syndrome |
| US7799766B2 (en) | 1998-04-08 | 2010-09-21 | Theta Biomedical Consulting & Development Co., Inc. | Composition for treating hormonally-dependent cancers |
| GB9911017D0 (en) * | 1999-05-13 | 1999-07-14 | Zeneca Ltd | Pharmaceutical compositions |
| AU4198899A (en) * | 1999-05-20 | 2000-12-12 | Par Pharmaceutical, Inc. | Stabilized composition based on pyridinyl-sulfinyl-benzimidazoles and process |
| WO2000074784A1 (en) * | 1999-06-09 | 2000-12-14 | Eli Lilly And Company | Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist |
| SE0000774D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| EP1370261A2 (en) * | 2001-03-08 | 2003-12-17 | AstraZeneca AB | New use |
| US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| MXPA03011017A (es) | 2001-06-01 | 2005-04-29 | Pozen Inc | Composiciones farmaceuticas para la entrega coordinada de nsaids. |
| SE0102993D0 (sv) | 2001-09-07 | 2001-09-07 | Astrazeneca Ab | New self emulsifying drug delivery system |
| US20040121004A1 (en) * | 2002-12-20 | 2004-06-24 | Rajneesh Taneja | Dosage forms containing a PPI, NSAID, and buffer |
| US20040185032A1 (en) * | 2003-03-18 | 2004-09-23 | David Burrell | Compositions and methods for treating colic |
| US7923043B2 (en) | 2004-03-30 | 2011-04-12 | Theta Biomedical Consulting & Development Co., Inc. | Method for protecting humans against superficial vasodilator flush syndrome |
| US7776873B2 (en) * | 2005-12-01 | 2010-08-17 | Yuhan Corporation | Method for treating damage to gastric mucosa |
| US8771643B2 (en) * | 2008-01-04 | 2014-07-08 | Schabar Research Associates Llc | Use of analgesic potentiating compounds to potentiate the analgesic properties of an analgesic compound |
| WO2010029335A1 (en) | 2008-09-09 | 2010-03-18 | Astrazeneca Uk Limited | Method for delivering a pharmaceutical composition to patient in need thereof |
| EP2445499A4 (en) | 2009-06-25 | 2013-02-27 | Astrazeneca Ab | METHOD FOR TREATING A PATIENT WITH RISK OF DEVELOPING A NSAID-ASSOCIATED SPURGE |
| US9176146B2 (en) | 2009-08-03 | 2015-11-03 | Theta Biomedical Consulting & Development Co., Inc. | Methods of treating autism spectrum disorders and compositions for same |
| US9050275B2 (en) | 2009-08-03 | 2015-06-09 | Theta Biomedical Consulting & Development Co., Inc. | Methods of screening for and treating autism spectrum disorders and compositions for same |
| CA2860231A1 (en) | 2011-12-28 | 2013-07-04 | Pozen Inc. | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
| CA3124579A1 (en) | 2020-07-15 | 2022-01-15 | Schabar Research Associates Llc | Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn |
| BR112023000598A2 (pt) | 2020-07-15 | 2023-01-31 | Schabar Res Associates Llc | Composições de dose oral unitária composta de ibuprofeno e famotidina para o tratamento da dor aguda e redução da gravidade e/ou risco de azia |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CY1398A (en) * | 1981-09-04 | 1987-12-18 | Glaxo Group Ltd | Pharmaceutical compositions containing non-steroidal anti-inflammatory agents |
| US4522826A (en) * | 1984-02-08 | 1985-06-11 | Richardson-Vicks Inc. | Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same |
| US4757060A (en) * | 1986-03-04 | 1988-07-12 | Bristol-Myers Company | Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers |
-
1990
- 1990-10-29 IN IN907/CAL/90A patent/IN171746B/en unknown
- 1990-10-29 NZ NZ235877A patent/NZ235877A/xx unknown
- 1990-10-31 CA CA002028746A patent/CA2028746C/en not_active Expired - Lifetime
- 1990-10-31 PT PT95753A patent/PT95753A/pt not_active Application Discontinuation
- 1990-10-31 AU AU65689/90A patent/AU646230B2/en not_active Ceased
- 1990-11-01 ES ES90311995T patent/ES2057439T3/es not_active Expired - Lifetime
- 1990-11-01 EP EP90311995A patent/EP0426479B1/en not_active Revoked
- 1990-11-01 ZA ZA908775A patent/ZA908775B/xx unknown
- 1990-11-01 KR KR1019900017661A patent/KR910009254A/ko not_active Ceased
- 1990-11-01 GR GR900100786A patent/GR1002097B/el not_active IP Right Cessation
- 1990-11-01 DE DE69006684T patent/DE69006684T2/de not_active Revoked
- 1990-11-01 AT AT90311995T patent/ATE101515T1/de not_active IP Right Cessation
- 1990-11-01 IE IE394690A patent/IE64953B1/en not_active IP Right Cessation
- 1990-11-02 JP JP2298713A patent/JPH03206052A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ATE101515T1 (de) | 1994-03-15 |
| CA2028746A1 (en) | 1991-05-03 |
| IE903946A1 (en) | 1991-05-08 |
| PT95753A (pt) | 1991-09-30 |
| JPH03206052A (ja) | 1991-09-09 |
| IN171746B (enExample) | 1992-12-26 |
| EP0426479A1 (en) | 1991-05-08 |
| EP0426479B1 (en) | 1994-02-16 |
| KR910009254A (ko) | 1991-06-28 |
| DE69006684T2 (de) | 1994-06-09 |
| IE64953B1 (en) | 1995-09-20 |
| DE69006684D1 (de) | 1994-03-24 |
| ZA908775B (en) | 1992-07-29 |
| ES2057439T3 (es) | 1994-10-16 |
| AU646230B2 (en) | 1994-02-17 |
| GR1002097B (en) | 1995-12-28 |
| AU6568990A (en) | 1991-05-09 |
| GR900100786A (el) | 1992-04-17 |
| NZ235877A (en) | 1992-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2028746C (en) | Pharmaceutical compositions and methods for treating the symptoms of overindulgence | |
| US5204118A (en) | Pharmaceutical compositions and methods for treating the symptoms of overindulgence | |
| US4749711A (en) | Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs | |
| JPH01503539A (ja) | 非鎮静抗ヒスタミン薬を含んでなる咳／風邪用混合物 | |
| US4757060A (en) | Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers | |
| US5025019A (en) | Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs | |
| JP5442178B2 (ja) | ロキソプロフェン含有経口用組成物 | |
| CA2020018A1 (en) | Method and composition for treating the migraine complex | |
| US5466436A (en) | Medicaments for treating inflammatory conditions or for analgesia | |
| CN1252725A (zh) | 止痛合剂 | |
| BG63329B1 (bg) | Лекарствени форми, съдържащи ибупрофен и кодеин | |
| JP3122748B2 (ja) | イブプロフェン含有解熱鎮痛剤 | |
| AU606638B2 (en) | Nonsteroidal anti-inflammatory drug composition containing h1 blockers, h2 blockers, beta-adrenergic agonists or combinations thereof and an alkalizing agent, and process for administration | |
| JP5403935B2 (ja) | 経口用の慢性疼痛予防または治療剤 | |
| Ament et al. | Prophylaxis and treatment of NSAID-induced gastropathy. | |
| US5071842A (en) | Aspirin-containing composition including diphenhydramine and an alkalizing agent to reduce gastrointestinal injury potential | |
| EP0674527A1 (en) | Use of s(+) antipodes of analgesic agents for the manufacture of a composition to treat respiratory disorders | |
| CA2785360A1 (en) | Treating critically ill patients with intravenous ibuprofen | |
| US4840962A (en) | Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs | |
| JP2008195705A (ja) | ロキソプロフェン含有経口用組成物 | |
| JP5296968B2 (ja) | イブプロフェン含有経口用医薬組成物 | |
| NZ206504A (en) | Pharmaceutical compositions containing hydroxyzine and non-steroidal anti-infammatory/analgesic agents and/or acetaminophen | |
| JP5742352B2 (ja) | 解熱鎮痛組成物 | |
| Diener et al. | Analgesics | |
| WO2006006577A1 (ja) | ロキソプロフェンを含有する経口投与用組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |